Simcere bought Endu, an innovative cancer drug, in 2006, prior to the IPO.
先声在2006年上市之前就收购一个创新性的抗癌药:恩度。
Simcere calls Bicun a "first-to-market, branded generic drug." Edaravone has been investigated heavily in Japan for use as a neuroprotectant.
先声称必存为“市场第一,品牌的仿制药。”在日本,对依达拉奉作为一种神经保护剂进行了大量研究。
I tend to like the smaller, overseas-listed companies like Simcere as they are often more entrepreneurial and adaptable to market conditions.
我比较倾向于较小、海外上市的企业,如先声药业,因为这些企业往往更具闯劲,更能灵活应变市场状况。
I tend to like the smaller, overseas-listed companies like Simcere as they are often more entrepreneurial and adaptable to market conditions.
我比较倾向于较小、海外上市的企业,如先声药业,因为这些企业往往更具闯劲,更能灵活应变市场状况。
应用推荐